Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.42 USD

39.42
1,066,227

-0.01 (-0.03%)

Updated Aug 5, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops

by Zacks Equity Research

Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.

    Zacks Equity Research

    Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

    by Zacks Equity Research

    Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

      Zacks Equity Research

      Roche (RHHBY) MS Drug FDA Review Date Extended in U.S.

      by Zacks Equity Research

      Roche (RHHBY) announced that the FDA has extended the PDUFA date for the review of the company's Biologics License Application (BLA) for Ocrevus.

        Zacks Equity Research

        Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

        by Zacks Equity Research

        Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

          Zacks Equity Research

          Merck (MRK) Offers Update on Keytruda-Halaven Combination

          by Zacks Equity Research

          Merck (MRK) and Eisai (ESALY) announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic TNBC.

            Zacks Equity Research

            Ophthotech Hits 52-Week Low on Unfavorable Fovista Data

            by Zacks Equity Research

            Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.

              Zacks Equity Research

              Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

              by Zacks Equity Research

              Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                Zacks Equity Research

                Biogen Presents Positive Early Data from Alzheimer's Study

                by Zacks Equity Research

                Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

                  Zacks Equity Research

                  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

                  by Zacks Equity Research

                  Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

                    Zacks Equity Research

                    Roche Presents Positive Follicular Lymphoma Data on Gazvya

                    by Zacks Equity Research

                    Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                      Zacks Equity Research

                      Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH

                      by Zacks Equity Research

                      Kite Pharma, Inc. (KITE) announced it has initiated a rolling submission of the Biologic License Application (BLA) for its lead pipeline candidate, KTE-C19, to the FDA.

                        Zacks Equity Research

                        Amgen/Allergan File for EU Approval of Avastin Biosimilar

                        by Zacks Equity Research

                        Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                          Zacks Equity Research

                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                          by Zacks Equity Research

                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                            Zacks Equity Research

                            Merck KGaA (MKGAF) Expands Distribution Deal with Roche

                            by Zacks Equity Research

                            Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

                              by Arpita Dutt

                              This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

                                Zacks Equity Research

                                Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

                                by Zacks Equity Research

                                Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

                                  Zacks Equity Research

                                  MedTech Industry Stock Outlook - December 2016

                                  by Zacks Equity Research

                                  The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.